Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Trazpiroben Tablet vs Capsule and Food Effect
NCT04831502Phase 1Withdrawn
- Sponsor
- Takeda
- Start
- Apr 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of trazpiroben in gastroparesis (2 arms), sponsored by Takeda. Primary endpoints: Geometric Mean Ratio of AUClast: Area Under the Concentration-time Curve From Time 0 to the Last Quantifiable Concentration Following TAK-906 Tablet Relative to TAK-906 Capsule Administration Under…, Geometric Mean Ratio of AUCinf Following TAK-906 Tablet Relative to TAK-906 Capsule Administration Under Fasted State and 1 more. Planned start Apr 2021; status: withdrawn.
02
Drugs
trazpiroben
03
Conditions
gastroparesis
Beyond the preview
Go deeper on NCT04831502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04831502.